Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center. The results, published in Cancer Discovery, prime the combination strategy for future clinical trials.
đ Full Story

Woman Gets Naked and SCREAMS on Southwest flight to Phoenix
- DAVID BLACKMON: OPEC Delivers Masterful Rebuke To Global Energy Agency Head - David Blackmon
- 15 Best Jobs For 11 Year Olds To Make Money In 2024 - Aamir Zahoor
- What To Know About Intussusception in Children and Adults - Sayaka Blickenderfer, PhD
- TikTok Management 101: How to Get Started and Earn Your First Dollar - Zoul
- The Connection Between Crohn's Disease and Skin Rashes - Cristina Mutchler
- Microsoft is making a Copilot AI assistant for gamers, but it's not clear what it does - Lawrence Bonk

Nothing Budget Phones: Worth the Hype? ft. Phone 3A
- Anthropic researchers forced Claude to become deceptive â what they discovered could save us from rogue AI - Michael Nuñez
- Columbia Punishes 22 Students for Building Takeover (Update: Another Arrest by ICE)
- Trump admin. fires USDA staff working on bird flu, immediately backpedals - Beth Mole
- Worried About a Recession? Make These 8 Money Moves Now
- Kids using litter boxes in school? Texas FURRIES bill seeks to stop 'non-human' behavior
- GFAL unveils beta for Diamond Dreams match-3 game with optional Web3 features - Dean Takahashi